Shots:
- The CHMP has granted positive opinion to the company’s fruquintinib (VEGFR-1, -2 & -3 inhibitor) for previously treated metastatic colorectal cancer (mCRC) adults. Takeda holds its exclusive global rights outside of mainland China, Hong Kong & Macau while HUTCHMED has China rights
- The opinion was based on P-III (FRESCO-2) study assessing fruquintinib + best supportive care (BSC) vs PBO + BSC in previously treated mCRC patients
- The study met both 1EPs and 2EPs demonstrating improved OS & PFS with consistent safety profile irrespective of previous studies. The data was published in The Lancet
Ref:Takeda | Image:Takeda | Press Release
Related News:- Takeda Partners with BridGene Biosciences to Identify Novel Small Molecules in Immunology and Neurology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
